Thomas Wall
Cardiovascular Disease · Greensboro, NCNPI 1528018314
Payments from drug & device makers
Across 139 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$470
- Lilly USA, LLC$362
- AstraZeneca$313
- Novo Nordisk$267
- Novartis$245
- Medtronic$110
- plus $763 from 16 others
What the payments were for
- Food & beverage$2,51199%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $470 |
| Lilly USA, LLC | 23 | $362 |
| AstraZeneca | 18 | $313 |
| Novo Nordisk | 15 | $267 |
| Novartis | 14 | $245 |
| Medtronic | 1 | $110 |
| Pfizer | 5 | $100 |
| GSK | 4 | $87 |
| Bayer | 4 | $79 |
| Phathom Pharmaceuticals, Inc. | 5 | $78 |
| Exact Sciences | 3 | $54 |
| Boehringer Ingelheim | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Mylan Specialty L.p. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Vertos Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,531 in reported general payments places this provider in the 50th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 606 | $475,109 |
| EliquisApixaban | 356 | $244,589 |
| Repatha SureclickEvolocumab | 42 | $37,054 |
| XareltoRivaroxaban | 33 | $26,557 |
| FarxigaDapagliflozin Propanediol | 28 | $24,007 |
| EntrestoSacubitril/Valsartan | 22 | $20,570 |
| BrilintaTicagrelor | 14 | $9,105 |
| Metoprolol Succinate | 542 | $4,928 |
| Losartan Potassium | 311 | $2,695 |
| Rosuvastatin Calcium | 169 | $2,154 |
| Potassium Chloride | 162 | $1,604 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 84 | $1,600 |
| Flecainide Acetate | 38 | $1,302 |
| Amlodipine Besylate | 264 | $1,103 |
| ClopidogrelClopidogrel Bisulfate | 85 | $1,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $53 | $475,109606 claims |
| PfizerEliquis | $100 | $244,589356 claims |
| AstraZenecaFarxiga, Brilinta | $313 | $33,11242 claims |
| Johnson & JohnsonXarelto | $18 | $26,55733 claims |
| NovartisEntresto | $245 | $20,57022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Greensboro
- Jagadeesh GanjiGreensboro$1.7M
- Kenneth HiltyGreensboro$1.6M
- Michael CooperGreensboro$613K
- Cameron LambertGreensboro$609K
- Bridgette ChristopherGreensboro$261K
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.